top of page

New Member: Welcome in our cluster to Panasome GmbH


Panasome GmbH - A new path to immunity. Panosome uses its novel, proprietary technology platform to generate antibodies to challenging disease targets. The VAST technology platform unlocks antibodies to small molecules, peptides, and proteins and the high on-target specificity of Panosome's antibodies limits side effects.


They focus their development pipeline on cancer indications with a very high medical need. For this, Panasome generates monoclonal antibodies against tumor-specific carbohydrates (such as MUC1) to target pancreatic cancer that expresses aberrantly glycosylated MUC-1 and a T cell receptor-like antibodies to target intracellular cancer antigens displayed on antigenic presenting cells.


Panasome applies this concept to specifically target a mutation connected to the rare disease midline glioma, an aggressive brain cancer that predominantly affects children.


We are looking forward to see your active participation in the network!


You can find here more information about Panasome GmbH.

Comments


bottom of page